Trial · NCT03446040
Results by group206
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 206
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 8 mg | Adverse Events (AEs) | 3 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 24 mg | Adverse Events (AEs) | 3 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 72 mg | Adverse Events (AEs) | 4 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 200 mg | Adverse Events (AEs) | 4 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 480 mg | Adverse Events (AEs) | 4 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 800 mg | Adverse Events (AEs) | 8 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 1200 mg | Adverse Events (AEs) | 2 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 1600 mg | Adverse Events (AEs) | 5 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 2400 mg | Adverse Events (AEs) | 8 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part B: BMS-986258 480 mg + NIVO 480 mg | Adverse Events (AEs) | 4 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part B: BMS-986258 800 mg + NIVO 480 mg | Adverse Events (AEs) | 11 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part B: BMS-986258 1200 mg + NIVO 480 mg | Adverse Events (AEs) | 6 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part B: BMS-986258 1600 mg + NIVO 480 mg | Adverse Events (AEs) | 17 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A1: BMS-986258 1200 mg + ENHANZE | Adverse Events (AEs) | 13 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 8 mg | Serious Adverse Events (SAEs) | 1 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 24 mg | Serious Adverse Events (SAEs) | 2 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 72 mg | Serious Adverse Events (SAEs) | 3 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 200 mg | Serious Adverse Events (SAEs) | 1 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 480 mg | Serious Adverse Events (SAEs) | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) | Part A: BMS-986258 800 mg | Serious Adverse Events (SAEs) | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03446040/results